Navigation Links
ERT Announces Upcoming Retirement of Michael McKelvey as Chief Executive Officer
Date:9/10/2010

PHILADELPHIA, Sept. 10 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (ERT), (Nasdaq: ERES), a global provider of technology and services to the pharmaceutical, biotechnology, and medical device industries, today announced that Michael McKelvey will be retiring from his positions as President and Chief Executive Officer and a director of ERT.  The Company's Board of Directors has begun a search for a successor.  Dr. McKelvey will continue in his current position until a successor is appointed or earlier, based on mutual agreement of Dr. McKelvey and the Board.

"I am honored to have led ERT for more than four years," commented Dr. McKelvey. "The acquisition of CareFusion Research Services and the emerging opportunities in healthcare represent a fundamental strategic shift in our business. The Company has transformed into a multi-product and service provider.  We have built a strong, well-diversified company that is very well positioned for growth in the future.  After over four years at the helm and at the age of 58, I feel the time is right to retire from this marvelous Company, focus on other interests, and devote more time to my family.  I leave ERT in a strong financial position, with a well diversified portfolio of products and services focused in cardiac safety, respiratory, multi-mode ePRO, and medical devices that can serve the research, pharmaceutical safety, and healthcare markets, a well thought out strategic vision and focus, and an excellent group of senior executives who individually and as a group are outstanding. We have achieved this due largely to the support of our employees, customers, the Board, and investors, and I would like to take this opportunity to thank them."  

Commenting on behalf of the Board of Directors, ERT's Chairman, Joel Morganroth, MD, said, "The Board accepts Mike's decision to retire with understanding and gratitude.  Mike leaves our Company positioned for future growth in the clinical research, pharmaceutical marketing, and healthcare markets.  The Board appreciates Mike's commitment to a successful transition while it conducts its search for a successor and wishes him the very best. The Company has retained Heidrick and Struggles, one of the nation's leading executive search firms, to assist in its search and will consider both internal and external candidates."

About eResearchTechnology, Inc.

Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com) is a global provider of technology and services to the pharmaceutical, biotechnology and medical device industries.  The Company is the market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development.  It is also a leading provider of centralized respiratory technology and services to evaluate pulmonary function efficacy and safety in clinical development.  ERT also provides solutions to streamline the clinical trials process by automating the collection, analysis, and distribution of ePRO clinical data using multi-mode technology in all phases of clinical development as well as providing selected medical devices for the clinical trials and healthcare industries.  

This release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect our current views as to future events.  These statements can be identified by the fact that they do not relate strictly to historical or current facts.  They use words such as "will," "will continue" and other words and terms of similar meaning in conjunction with a discussion of future events.  These statements are subject to risks and uncertainties that could cause actual events to differ materially from those expressed or implied in the forward-looking statements. Factors that might cause such a difference include unanticipated delays in recruiting a suitable successor for Dr. McKelvey or changes in Dr. McKelvey's ability or willingness to continue to serve during this transition process.

Forward-looking statements speak only as of the date made.  We undertake no obligation to update any forward-looking statements, including prior forward-looking statements, to reflect the events or circumstances arising after the date as of which they were made.  As a result of these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements included in this release or that may be made in our filings with the Securities and Exchange Commission or elsewhere from time to time by, or on behalf of, us.


'/>"/>
SOURCE eResearchTechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sysmex America Announces LabCorp Hematology Automation Agreement
2. K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market
3. Pharmacyclics Announces Date of Fiscal Year End 2010 Financial Results and Conference Call and Presentation at Stifel Nicolaus Healthcare Conference
4. Business & Decision North America Announces the Successful Go-Live of Microsoft Dynamics AX at DeVilbiss Healthcare
5. Misonix Announces New Distribution Agreement For Spain
6. Dehaier Medical Systems Announces Engagement of RedChip Companies to Lead Public and Investor Relations
7. Meditrina Pharmaceuticals, Inc. Announces Allowance of Patent for Treatment of Endometriosis
8. ResMed Inc. Announces Completion of Two-for-One Stock Split
9. Trubion Pharmaceuticals Announces Early Termination of HSR Waiting Period
10. Halozyme Therapeutics Announces Public Offering of Common Stock
11. Stereotaxis Announces First-Ever, Prospective, Comparative Clinical Trial Outcome for VT Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... DUBLIN , Mar. 23, 2017 Research ... Valve Devices Market: Analysis By Procedure, Replacement Procedure By Technique, Repair ... their offering. ... Global Heart Valve Devices Market is forecasted to grow at a ... heart valve devices is driven by rising aging population, growth in ...
(Date:3/23/2017)... INDIANAPOLIS , March 23, 2017  Eli ... the William Sansum Diabetes Center have established a research ... by diabetes through enhanced research, education and care. ... disease bears a disproportionate weight on Latino families in ... David Kerr , M.D., FRCPE, director of Innovation and ...
(Date:3/23/2017)... 2017 Summary ... pipeline guide Primary Hyperoxaluria - Pipeline Review, H1 ... (Genito Urinary System And Sex Hormones) pipeline landscape. ... by recurrent kidney and bladder stones. It results ... Symptoms include blood in the urine, pain when ...
Breaking Medicine Technology:
(Date:3/24/2017)... San Diego, Calif. (PRWEB) , ... March 24, ... ... (ADI) has raised over $100,000 for its innovative EcoQube Frame vertical micro-veggies garden ... demonstrates the instant demand for the product – with nearly 2,000 consumers (and ...
(Date:3/24/2017)... ... March 24, 2017 , ... Viewers who like to educate ... historical facts, cultural practices, goods, services, and societal issues tend to appreciate and love ... the popular practice of utilizing running events for causes around the world. ...
(Date:3/24/2017)... ... ... “End Time GPS”: a dauntless and enlightened study of the second-coming ... the creation of published author, Wesley Gerboth, a World War II veteran, with a ... Now, at age ninety-one, he shares the Wisdom God bestowed upon him in this ...
(Date:3/23/2017)... ... ... A recent report from the National Council on Teacher Quality (NCTQ) advocates for ... on a review of GPA and SAT/ACT requirements at 221 institutions in 25 states, ... that this higher bar should be set by states, by the Council for the ...
(Date:3/23/2017)... ... 23, 2017 , ... The IoT (Internet of Things) is revolutionizing the way ... impact on businesses and individual consumers alike. Laboratories can maximize their profit margin ... anywhere from $4 trillion to $11 trillion dollars by the year 2025. McKinsey expects ...
Breaking Medicine News(10 mins):